NEW YORK, July 27, 2021 /PRNewswire/ -- AIkido Pharma
Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced
that the U.S. Patent and Trademark Office has issued a Notice of
Allowance for application No.: 16/477,125.
This technology relates to the use of novel and proprietary
central nervous system (CNS) homing peptides. This technology
has been exclusively sublicensed to AIkido Pharma for use of
psilocybin for the therapeutic treatment of neuroinflammatory
disease in cancer patients.
The homing peptides covered under the Notice of Allowance and
the sublicense, can be used to facilitate the delivery of
therapeutic agents to inflamed CNS tissue. Psychedelics such
as psilocybin have been shown to have anti-inflammatory activity in
addition to their potential efficacy for treatment of neurological
disorders such as anxiety, depression and post-traumatic stress
disorder (PTSD). Studies indicate that neuroinflammation of
the brain and other CNS tissues in cancer patients contributes to,
among other symptoms, the onset of cancer cachexia, which is
characterized by loss of appetite, extreme weight loss and muscle
wasting.
Anthony Hayes, CEO of AIkido
Pharma, stated, "We are pleased that a Notice of Allowance was
issued for this technology. We believe that the psychological
impacts of cancer are significant, and treatment of these impacts
represent a substantial unmet need. We are working to develop
this technology as part of our diversified platform and view this a
step forward in those efforts."
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a
biotechnology Company with a diverse portfolio of small-molecule
anti-cancer therapeutics. The Company's platform consists of
patented technology from leading universities and researchers and
we are currently in the process of developing an innovative
therapeutic drug platform through strong partnerships with world
renowned educational institutions, including The University
of Texas at Austin and University
of Maryland at Baltimore. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer and prostate
cancer. We are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology. The Company is also
developing a broad-spectrum antiviral platform that may potentially
inhibit replication of multiple viruses including Influenza virus,
SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.:
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/notice-of-allowance-issued-for-central-nervous-system-peptide-technology-301341973.html
SOURCE AIkido Pharma Inc.